| Article ID | Journal | Published Year | Pages | File Type | 
|---|---|---|---|---|
| 5655200 | Diabetes & Metabolism | 2017 | 10 Pages | 
Abstract
												Over a 3-year follow-up period, our results showed no difference in risk of a major clinical event among patients, regardless of whether or not they achieved their personalized recommended HbA1c target. These results need to be confirmed before implementing a more permissive strategy for treating T2DM in elderly patients.
											Related Topics
												
													Health Sciences
													Medicine and Dentistry
													Endocrinology, Diabetes and Metabolism
												
											Authors
												S. Bucher, H. Panjo, A. Al-Salameh, B. Bauduceau, L. Benattar-Zibi, P. Bertin, G. Berrut, E. Corruble, N. Danchin, G. Derumeaux, J. Doucet, B. Falissard, F. Forette, O. Hanon, R. Ourabah, F. Pasquier, C. Piedvache, M. Pinget, V. Ringa, 
											